Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

Ferring

Status and phase: Terminated; Phase 2

Conditions: Prostate Cancer

Treatments: Drug: Degarelix

Study type: Interventional

Funder types: Industry

Identifiers

NCT00117312

FE200486 CS06A

Details and patient eligibility

About

Participants responding well in Study FE200486 CS06 (NCT00117949) were given the opportunity to continue treatment with degarelix under a clinical study until FE200486 was available on the market or until the study was discontinued.

Study FE200486 CS06A was to provide knowledge of the long-term safety and tolerability of FE200486.

Full description

The data include participants from both the main study (FE200486 CS06; NCT00117949) and the extension study FE200486 CS06A.

Enrollment: 37 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Each patient must meet the following inclusion criteria before entry into the study:

• Has given written consent before any study related activity is performed. A study related activity is defined as any procedure that would not have been performed during the normal management of the patient.
• Has had sufficient testosterone suppression (as defined in the withdrawal criteria of FE200486 CS06) for at least 28 days.

Exclusion criteria

Any patient meeting any of the following exclusion criteria will not be entered into the study:

• Has been withdrawn from Study FE200486 CS06 due to an adverse event, failure to achieve at least 28 days of testosterone suppression, insufficient prostate-specific antigen (PSA) suppression as defined in Study FE200486 CS06 in the absence of concomitant rise in testosterone level or non-compliance with protocol required procedures.
• Requires hormonal therapy for neoadjuvant purposes.
• Requires treatment with any other drug modifying the testosterone level or function.
• Is considered to be a candidate for curative therapy, i.e., radical prostatectomy or radiotherapy, within 6 months after Visit 1.
• Has a history of severe asthma requiring daily treatment with inhalation steroids, angioedema or anaphylactic reactions.
• Has hypersensitivity towards any component of the investigational product.
• Has had a cancer disease within the last 10 years except for prostate cancer, and surgically removed basocellular or squamous cell carcinoma of the skin.
• Has a clinically significant neurologic, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, dermatological or infectious disorder or any other condition, including excessive alcohol or drug abuse, which may interfere with trial participation or which may affect the conclusion of the study, as judged by the investigator.
• Any clinically significant laboratory abnormalities which, in the judgment of the investigator, would interfere with the patient's participation in this study or evaluation of study results (liver transaminases and bilirubin must be within normal limits).
• Has a mental incapacity or language barrier precluding adequate understanding or co-operation.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

37 participants in 4 patient groups

Degarelix 40 mg

Experimental group

Description:

Degarelix 40 mg (10 mg/mL)

Treatment:

Drug: Degarelix

Drug: Degarelix

Drug: Degarelix

Drug: Degarelix

Degarelix 80 mg

Experimental group

Description:

Degarelix 80 mg (20 mg/mL)

Treatment:

Drug: Degarelix

Drug: Degarelix

Drug: Degarelix

Drug: Degarelix

Degarelix 120 mg

Experimental group

Description:

Degarelix 120 mg (30 mg/mL)

Treatment:

Drug: Degarelix

Drug: Degarelix

Drug: Degarelix

Drug: Degarelix

Degarelix 160 mg

Experimental group

Description:

Degarelix 160 mg (40 mg/mL)

Treatment:

Drug: Degarelix

Drug: Degarelix

Drug: Degarelix

Drug: Degarelix